Location History:
- Westfield, MA (US) (2005)
- Arlington, VA (US) (2014)
- Arlington, MA (US) (2012 - 2017)
- Needham, MA (US) (2020)
Company Filing History:
14 out of 2,285 
6 out of 7 
1 out of 1 
Years Active: 2005-2020
Title: Rebecca L. Horan: Innovator in Silk-Based Pharmaceuticals
Introduction
Rebecca L. Horan, based in Arlington, MA, is a distinguished inventor with an impressive portfolio of 22 patents. Her innovative work primarily focuses on silk fibroin-based pharmaceutical formulations, which have the potential to revolutionize the field of drug delivery and therapeutics.
Latest Patents
Among her latest patents, Rebecca has developed compositions that encompass pure silk fibroin-based protein fragments, which are notably devoid of sericin. These compositions exhibit a molecular weight range from about 17 kDa to about 38 kDa and demonstrate a polydispersity between 1.5 and 3.0. The formulations are designed to be substantially homogeneous and maintain low levels of inorganic and organic residuals, ranging from 0 ppm to about 500 ppm. This innovative approach highlights the versatility and stability of silk proteins in pharmaceutical applications.
Career Highlights
Rebecca has made significant contributions to companies such as Allergan, Inc. and Silk Therapeutics, Inc. Her work has been pivotal in advancing the use of silk proteins in therapeutic formulations, enabling improved biocompatibility and efficacy in drug delivery systems.
Collaborations
Throughout her career, Rebecca has collaborated with talented professionals, including Gregory H. Altman and Jingsong Chen. Their collective expertise has fostered a dynamic environment for innovation and research in the application of silk proteins.
Conclusion
Rebecca L. Horan stands out as a leading inventor in the realm of silk-based pharmaceuticals. Her groundbreaking patents and collaborations underscore her commitment to advancing scientific knowledge and developing innovative solutions in healthcare. Her work promises to pave the way for new therapeutic possibilities, significantly impacting the pharmaceutical landscape.